Medical Therapeutics

Singulex, Inc.

Brief Description

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The...

OptoCeutics

Brief Description

Advancing non-invasive light technologies to stimulate the brain and improve cognitive function.

Through clinical trials, Optoceutics tests and develop solutions to treat and diagnose neurodegenerative diseases using emerging gamma stimulation therapy and digital biomarkers.

40 Hz light for gamma stimulation has been shown to improve memory and cognitive performance in a mouse model of Alzheimer's disease. 40 Hz light stimulation reduced amyloid plaque associated with Alzheimer's disease in the brain of mice by about 50%. Optoceutics develops a masked 40 Hz...

OncoRx Pharmaceuticals, Inc.

Brief Description

OncoRx Pharmaceuticals is an early-stage pharmaceutical company discovering and developing targeted therapies that control the progression of invasive malignant cancer. OncoRx has identified and tested drugs that markedly alter the sustained directional mobility, the uncontrolled cell cycle, and t​​he unrestrained growth and proliferation of intrinsically and acquired therapy-resistant tumors. Unlike non-aggressive primary tumors, the growth, progression and invasiveness of therapy-resistant tumors are not effectively controlled with currently available cancer therapies...

Omniox, Inc.

Brief Description

Omniox is an early stage biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia (oxygen deficiency) impacts cancer, cardiovascular diseases, trauma and many other conditions. At Omniox, we have engineered an unusually stable oxygen carrier technology (H-NOX) to deliver oxygen into hypoxic tissues and improve the treatment of severe unmet medical needs. We believe our approach overcomes the modes of failure of prior efforts in the field of oxygen therapeutics.

Timeline 2006. Company founded. Inventors

Elizabeth...

Ogma Scientific

Brief Description

Ogma Scientific works with clients in the energy, mining and agriculture sectors and clients in the chemical industry to identify innovative treatment strategies for problems in industrial ecosystems. Our high-throughput screening services are uniquely tailored to identify successful treatments to stop undesirable microbial activity that impacts industrial processes. Examples include biosouring in the oil sector and acid mine drainage in the mining sector. Biosouring alone, caused by the inadvertent stimulation of microbial activity during oil or gas recovery, costs the...

Nurix

Brief Description Nurix is pioneering rational drug design in the emerging field of protein regulation by targeting E2 conjugating enzymes and E3 ligases that control the Ubiquitin Proteasome System (UPS).

Regulation of protein stability by the UPS is modulated by the activity of these E2 and E3 enzymes, which control the tagging of proteins with ubiquitin for degradation by the proteasome. The human genome encodes approximately 1,000 different E3 ligases and 60 E2 enzymes. A number of these ligases recently have been shown to play key roles in human diseases, particularly in cancer and...

Libraria, Inc.

Brief Description

Libraria Inc. is using computational techniques to discover new small-molecule drugs that can be administered orally. Its proprietary technology enables the company and its partners to leverage known molecular structures, chemistry protocols, and bioactivity data to speed the chemistry phase of drug discovery by up to 50%.

Timeline

2000. Company founded.

2003. Acquired by Eidogon-Sertanty.

Inventors Jonathan Ellman

Iris Micromedical, Inc.

Brief Description

Drug delivery based on microstructural devices that administer therapeutic agents to selected target sites for treatment.

Iris Micromedical was focused on the development of UC Berkeley Associate Professor of Engineering Mauro Ferrari's silicon particulate technology for the intravascular targeted treatment of cancer imedd.

Four years after founding Iris Micromedical, Dr. Ferrari moved to Ohio State University as a professor of bioengineering, internal medicine, and mechanical engineering, and reformed the company as IMedd, Inc.

Timeline 1995....

Intellia

BRIEF DESCRIPTION Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. Intellia leverages leading scientific expertise, clinical development experience, and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class. Timeline 2014. Company founded. INVENTOR Jennifer Doudna

CalGen Therapeutics

Brief Description

Developer of a therapeutic inhaled antisense technology designed to prevent and treat respiratory infections.

Timeline 2021. Company founded Inventors

Kasper Karstensen, Sakari Kauppinen, Anders Michael Naar, Chi Zhu